Bimekizumab Efficacy and Safety through Three Years in Patients With Moderate to Severe Plaque Psoriasis: Long-Term Results from the BE SURE Randomized Controlled Trial and the BE BRIGHT Open-Label Extension. J of Skin 2022, 6 (6), s68. https://doi.org/10.25251/skin.6.supp.68.